# Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

> **NCT02512497** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Cutaneous T-cell Lymphoma
- T-Prolymphocytic Leukemia
- T-Large Granulocytic Leukemia
- T-Lymphoblastic Leukemia/Lymphoma
- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **PROCEDURE:** Stem Cell Transplant
- **DRUG:** Thymoglobulin

## Key facts

- **NCT ID:** NCT02512497
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-08
- **Primary completion:** 2023-10-06
- **Final completion:** 2025-06-18
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02512497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02512497, "Romidepsin Maintenance After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02512497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*